Medical News Today -
26 Sep 2013 11:00
Merck Serono, the biopharmaceutical division of Merck, has announced the decision to continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) under a new Phase III trial called START2 for patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). This announcement is based on the outcome of the START trial. The START trial did not meet the primary endpoint of improving overall survival (OS) ...
Share this Article